



INFORMATION REQUIRED U/S 160 AND 168 OF THE COMPANIES ACT, 2013 READ WITH RULE 13 AND RULE 15 OF THE COMPANIES (APPOINTMENT AND QUALIFICATIONS OF DIRECTORS) RULES, 2014

**&
Disclosure under Regulation 30(8) of SEBI (LODR) 2015**

SR. NO	NAME OF EVENT	EFFECTIVE DATE
1	Resignation of Mr. Bhikhabhai Chimanlal Shah	08/04/2015
2	Resignation of Mr. Kaushal Kamlesh Shah	05/01/2017
3	Resignation of Mr. Rajendra Rambhai Patel	05/01/2017
4	Appointment of Mr. Kirit Nanubhai Shelat as an Independent Director of the Company	03/02/2017
5	Appointment of Mrs. Vijaya Sampath as an Independent Director of the Company	03/02/2017
6	Appointment of Mr. Rajiv Gulati as an Independent Director of the Company	03/02/2017
7	Appointment of Mr. Shardul Suresh Shroff as an Independent Director of the Company	03/02/2017
8	Resignation of Mr. Sanjiv Kaul	26/05/2017
8	Resignation of Mr. Rajiv Gulati	06/10/2017
9	Resignation of Mr. Shardul Suresh Shroff	01/02/2018
10	Appointment of Mr. Prashant Gupta as an additional Independent Director of the Company	30/04/2018
11	Resignation of Mr. Himanshu Shah	31/05/2020
12	Appointment of Mr. Kaushal Kamlesh Shah as an additional Director of the Company	04/08/2020
13	Resignation of Dr. Kirit Shelat as Independent Director of the company	11/09/2020
14	Appointment of Mr. Rajeev Dalal as an Additional Independent Director of the Company	19/12/2020
15	Appointment of Mr. Krishnakumar Vaidyanathan as an additional director of the company	20/12/2020
16	Appointment of Ms. Kalpana Unadkat as an Additional Independent Director of the company	05/01/2021

Last Updated on 06/01/2021

For Eris Lifesciences Limited

Milind Talegaonkar
Company Secretary

Registered & Corporate Office:

8th Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India

Phone: +91 - 79 - 30451111 / 30179400 - 03 • Fax: +91 - 79 - 30179404 / 30451001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in

CIN: L24232GJ2007PLC049867



Date: 6th January, 2021

To BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001	To National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai-400051
Security Code: 540596	Symbol: ERIS

SUBJECT: APPOINTMENT OF MS. KALPANA UNADKAT AS AN ADDITIONAL INDEPENDENT DIRECTOR OF THE COMPANY

Dear Sir/Madam,

In terms of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we wish to inform you that based on the recommendation of the Nomination and Remuneration Committee and their own consideration, the Board of Directors have approved the appointment of Ms. Kalpana Unadkat (DIN : 02490816) as an "Additional Director (Non-Executive Independent Director)" on the Board of the Company for a term of 5 (five) years starting from 5th January, 2021, by means of a circular resolution on 5th January 2021. The said appointment is subject to approval of the general body, in the usual course.

Profile Summary of Ms. Kalpana Unadkat: Ms. Kalpana Unadkat is a qualified Solicitor registered with the Bombay Incorporated Law Society and the Law Society of England & Wales. She brings over two decades of legal experience and is presently a Partner with Khaitan & Co. Prior to Khaitan & Co., Ms. Unadkat spent 10 years with the London offices of Ashurst LLP. She is a well-recognised expert on M&A and Corporate Governance principles. She also advises on board effectiveness, particularly around issues of corporate governance, leadership, organisational climate, and decision-making. In this regard, she has led several workshops and trained more than 300 directors with a comprehensive approach to director development. She is also an independent director on the board of public companies (listed and unlisted). She is a co-author of the research "Women on Board" and has been frequently quoted in the media on corporate governance and M&A deals in India.

Ms. Kalpana Unadkat is not related to any other existing Director of the Company and is not debarred from holding the office by virtue of any SEBI Order or any other authority.

Thanking You.

For Eris Lifesciences Limited

Milind Talegaonkar
Company Secretary & Compliance Officer

Registered & Corporate Office:

8th Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India

Phone: +91 - 79 - 30451111 / 30179400 - 03 • Fax: +91 - 79 - 30179404 / 30451001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in

CIN: L24232GJ2007PLC049867



Date: 21th December, 2020

To BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001	To National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai-400051
Security Code: 540596	Symbol: ERIS

SUBJECT: APPOINTMENT OF MR. KRISHNAKUMAR VAIDYANATHAN AS AN ADDITIONAL DIRECTOR OF THE COMPANY

Dear Sir/Madam, —

In terms of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we wish to inform you that based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors have passed a circular resolution on December 20, 2020, approving the appointment of Mr. Krishnakumar Vaidyanathan (DIN : 08976508) as an "Additional Director" Executive on the Board of Directors of the Company with effect from December 20, 2020 until the date of the ensuing Annual General Meeting ("AGM") of the Company or the last date on which the AGM should have been held, Whichever is earlier. The brief profile of Mr. Krishnakumar Vaidyanathan is given below:

Profile Summary of Mr. Krishnakumar Vaidyanathan:

Mr. Krishnakumar has over 22 years of professional experience across Lifesciences, Corporate Finance and Management Consulting; his areas of expertise include Strategic Planning, Business Building, Mergers & Acquisitions, Corporate Finance and Operational Excellence. Prior to Eris, Mr. Krishnakumar was a Corporate Finance Partner with Ernst & Young LLP for 9 years. Prior to Ernst & Young LLP, Mr. Krishnakumar has worked with Avendus Capital, Piramal Pharma Solutions and McKinsey & Co. Mr. Krishnakumar holds degree of Masters in business finance from IIM Calcutta and a B.Tech from Veermata Jijabai Technological Institute, Mumbai University.

Mr. Krishnakumar Vaidyanathan is not related to any other existing Director of the Company and is not debarred from holding the office by virtue of any SEBI Order or any other authority.

Thanking You,

For Eris Lifesciences Limited

Milind Talegaonkar
Company Secretary & Compliance Officer

Registered & Corporate Office:

8th Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India

Phone: +91 - 79 - 30451111 / 30179400 - 03 • Fax: +91 - 79 - 30179404 / 30451001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in

CIN: L24232GJ2007PLC049867



Date: 20th December, 2020

To BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001	To National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai-400051
Security Code: 540596	Symbol: ERIS

SUBJECT: Appointment of Mr. Rajeev Dalal as an Additional Independent Director of the

Company Dear Sir/Madam,

In terms of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we wish to inform you that based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors have passed a circular resolution on December 19, 2020, approving appointment of Mr. Rajeev Dalal (DIN : 00222650) as an "Additional Director (Non-Executive Independent Director)" on the Board of Directors of the Company with effect from December 19, 2020 for a term of 5 (five) years upto December 18, 2025, subject to approval of the Shareholders of the Company. The brief profile of Mr. Rajeev Dalal is given below:

Profile Summary of Mr. Rajeev Dalal: Mr. Rajeev Dalal is a Member of the Institute of Company Secretaries of India. Further he also holds degree of Bachelor of Law and Bachelor of Commerce. He has also been a member of the Committee appointed by the Securities Exchange Board of India (SEBI) for improving disclosure standards in public documents of Corporates for Capital issues. He has over 35 years of Corporate Finance experience covering 100+ M&A (domestic and cross border) transactions and Private Equity deals in sectors such as Pharma, Chemicals, FMCG, Metals & Mining, Industrials and Financial Services. He was associated with Ernst & Young LLP as transactions partner in 2002, prior to that he was associated with Ind Global Finance Trust (a category 1 investment bank), HSBC and JM Financial in their investment banking divisions.

Mr. Rajeev Dalal is not related to any other existing Director of the Company and is not debarred from holding the office by virtue of any SEBI Order or any other authority.

Thanking You,

For Eris Lifesciences Limited

Milind Talegaonkar
Company Secretary & Compliance Officer

Registered & Corporate Office:

8th Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India

Phone: +91 - 79 - 30451111 / 30179400 - 03 • Fax: +91 - 79 - 30179404 / 30451001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in

CIN: L24232GJ2007PLC049867



EY Entrepreneur of the year-2013



FROST & SULLIVAN
2013
BEST PRACTICES AWARD
Competition Strategy Leadership Award, India



Business today/YES bank
Excellence Awards-2013



Date: 11th September, 2020

To BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001	To National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai-400051
Security Code: 540596	Symbol: ERIS

SUBJECT: INTIMATION OF RESIGNATION OF INDEPENDENT DIRECTOR OF THE COMPANY

Dear Sir / Madam,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulation) read with Para A of Part A of Schedule III of the said Regulations, we hereby inform that Dr. Kirit Nanubhai Shelat (DIN: 00190619) has tendered his resignation from the position of Independent Director of the Company with effect from 11th September, 2020. The details required under Regulation 30 of the Listing Regulations, read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015, are given as under.

Sr. No.	Disclosure Requirement	Details
1	Reason for change in directors	Resignation on account of increase in the volume of professional and personal commitments outside the company of the concerned Director.
2	Date of cessation	11 th September, 2020

Further, the Company has received the confirmation from Dr. Kirit Shelat that there are no other material reasons for his resignation other than those which are provided in the resignation letter dated 11th September, 2020. The said resignation letter incorporating the aforesaid confirmation is enclosed herewith.

You are requested to take the same on record.
Thanking You,

For Eris Lifesciences Limited

Milind Talegaonkar
Company Secretary & Compliance Officer

Encl: A/a

Registered & Corporate Office:

8th Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India

Phone: +91 - 79 - 30451111 / 30179400 - 03 • Fax: +91 - 79 - 30179404 / 30451001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in

CIN: L24232GJ2007PLC049867



Date: 05th August, 2020

To BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001	To National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai-400051
Security Code: 540596	Symbol: ERIS

SUBJECT: OUTCOME OF THE BOARD MEETING HELD ON AUGUST 4, 2020

Dear Sir/Madam,

In accordance with the provisions of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors of the Company at their meeting held on August 4, 2020 has inter alia, transacted the following business:

- To convene the Annual General Meeting (AGM) of the Members of the Company on Tuesday, September 29, 2020.
- Appointment of Mr. Kaushal Kamlesh Shah (DIN: 01229038) as an additional Director of the Company, w.e.f. August 04, 2020 until the ensuing Annual General Meeting of the members of the Company to be held in calendar year 2020. The brief profile of Mr. Kaushal Kamlesh Shah is given below:

Mr. Kaushal Kamlesh Shah is the head of manufacturing and distribution at our Company. He holds a bachelor's degree in commerce from the Gujarat University and a post graduate diploma in management from Som-Lalit Institute of Management Studies. He has more than 10 years of experience in the pharmaceutical industry, having also have previously worked with companies in the pharmaceutical sector. Mr. Kaushal Kamlesh Shah has been associated with our Company since 2007 as one the Directors on the Board. He resigned from the Board on January 5, 2017. Mr. Kaushal Kamlesh Shah currently is a Director on the Board of our subsidiaries, namely, Eris Therapeutics Private Limited, Kinedex Healthcare Private Limited, UTH Healthcare Limited, Aprica Healthcare Limited and Eris Healthcare Private Limited.

Mr. Kaushal Kamlesh Shah is not related to any other existing Director of the Company and is not debarred from holding the office by virtue of any SEBI Order or any other authority.

Thanking You,

For Eris Lifesciences Limited

Milind Talegaonkar
Company Secretary & Compliance Officer

Registered & Corporate Office:

8th Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India

Phone: +91 - 79 - 30451111 / 30179400 - 03 • Fax: +91 - 79 - 30179404 / 30451001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in

CIN: L24232GJ2007PLC049867



Date: June 01, 2020

To BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001	To National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai-400051
Security Code: 540596	Symbol: ERIS

Subject: Cessation in Directorship

Dear Sir / Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with clause 7 of circular CIR/CFD/CMD/4/2015 dated September 09, 2015, the Company hereby notifies a cessation in the Whole Time Directorship of Mr. Himanshu Shah (DIN: 01301025).

Mr. Himanshu Shah, had resigned from the Directorship of the Company on 16th July, 2019 and, at the request of the Company, had agreed to keep serving till 31st May 2020.

Mr. Himanshu Shah, continues to be associated with the Company as employee as

before. **For Eris Lifesciences Limited**

Milind Talegaonkar

Company Secretary & Compliance Officer

Registered & Corporate Office:

8th Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India

Phone: +91 - 79 - 30451111 / 30179400 - 03 • Fax: +91 - 79 - 30179404 / 30451001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in

CIN: L24232GJ2007PLC049867



EY Entrepreneur of the year-2013



FROST & SULLIVAN Best Practices-2013



Business today/YES bank Excellence Awards-2013



Date: September 30, 2019

The Manager Dept. of Corporate Services BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai 400 001 Scrip Code: 540596	The Asst Vice President Listing Department National Stock Exchange of India Limited Exchange Plaza, C-1, Block G Bandra – Kurla Complex, Mumbai 400051 Symbol: ERIS
---	--

Sub: Extension of the relieving date of Mr. Himanshu Shah as Whole Time

Director Dear Sir,

Pursuant to Regulation 30 of the Listing Regulations and other applicable provisions of law, we wish to inform you that, the members of the Board of the Company approved the extension of the relieving date of Mr. Himanshu Shah as Whole Time Director, with his due consent, to 31st May, 2020 through a circular resolution passed today, i.e. September 30, 2019.

This above is for your information and record please.

Thanking you,

Yours faithfully,

For Eris Lifesciences Limited

Milind Talegaonkar
Company Secretary & Compliance Officer

Registered & Corporate Office:

8th Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India

Phone: +91 - 79 - 30451111 / 30179400 - 03 • Fax: +91 - 79 - 30179404 / 30451001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in

CIN: L24232GJ2007PLC049867



Date: July 3, 2019

The Manager
Dept. of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001
Scrip Code: 540596

The Asst Vice President
Listing Department
National Stock Exchange of India
Limited
Exchange Plaza, C-1, Block G
Bandra – Kurla Complex,
Mumbai 400051
Symbol: ERIS

Dear Sir,

Sub: Outcome of the meeting of the Board of Directors of Eris Lifesciences Limited (Company) held today, i.e. on July 3, 2019

Pursuant to Regulation 30 of the Listing Regulations and other applicable provisions of law, we wish to inform you that, the Board of Directors of the Company at its meeting held today, i.e. July 3, 2019 has inter-alia:

1. Approved buyback proposal for purchase by the Company of its own fully paid equity shares of Re. 1 each (Equity Share) up to 17,39,130 Equity Shares (being ~1.26% of the total paid-up equity capital of the Company) at a price of Rs. 575/- (Rupees Five hundred seventy five only) per Equity Share, for a maximum aggregate consideration not exceeding Rs. 100 crore (Rupees One hundred crore Only) [excluding any expenses incurred or to be incurred for the Buyback like filing fees payable to the Securities and Exchange Board of India, if any, brokerage, applicable taxes (such as securities transaction tax, stamp duty and goods and service tax), advisors' fees, public announcement publication expenses, printing and dispatch expenses and other incidental and related expenses], being less than 25% of the aggregate paid-up equity share capital and free reserves (including securities premium account) of the Company as on March 31, 2019 (hereinafter referred to as the Buyback) from the shareholders of the Company on a proportionate basis through the tender offer route in accordance and consonance with the provisions contained in the Companies Act, 2013 and the Securities and Exchange Board of India (Buy Back of Securities) Regulations, 2018 (Buyback Regulation) (including any statutory modification(s) or re-enactment of the Companies Act, 2013 or Buyback Regulation). The public announcement setting out the process, timelines and other statutory details will be released in due course in accordance with the Buyback Regulation. The Board has designated the Executive Committee to act as Buyback and Executive Committee (the "Buyback Committee / Committee") and has delegated its powers to the Buyback Committee to do all such acts, deeds, matters and things as it may, in its absolute discretion, deem necessary, expedient, usual or proper in connection with the Buyback. The pre-Buyback shareholding pattern of the Company as on June 28, 2019 is attached hereto as Annexure A and the post Buy-Back shareholding pattern and actual securities bought back (in number and percentage) of the existing paid up capital will be provided on completion of the Buy-Back.

Registered & Corporate Office:

8th Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India

Phone: +91 - 79 - 30451111 / 30179400 - 03 • Fax: +91 - 79 - 30179404 / 30451001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in

CIN: L24232GJ2007PLC049867



2. Noted that the Promoters and Promoter Group of the Company have expressed their intention to not participate in the Buyback.

3. Fixed Monday, July 15, 2019 as the Record Date for the purpose of determining the entitlement and the names of equity shareholders who are eligible to participate in the Buyback.

4. Extended the relieving date of Mr. Himanshu Shah as Whole Time Director, with his due consent, from 16th July, 2019 to 30th September, 2019.

The meeting of the Board of Directors commenced at 11:15 a.m. and closed at 12:55 p.m.

This above is for your information and record please.

Thanking you,

Yours faithfully,

For Eris Lifesciences Limited

Milind Talegaonkar
Company Secretary & Compliance Officer

Encl: As above

Registered & Corporate Office:

8th Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India

Phone: +91 - 79 - 30451111 / 30179400 - 03 • Fax: +91 - 79 - 30179404 / 30451001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in

CIN: L24232GJ2007PLC049867



EY Entrepreneur of the year-2013



FROST & SULLIVAN
2013 BEST PRACTICES AWARD
Corporate Strategy Leadership Award-2013



Business today/YES bank
Excellence Awards-2013



Date: May 1, 2018

To The Department of Corporate Services BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001 Security Code: 540596	To National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai-400051 Symbol: ERIS
---	--

Re: Appointment of Mr. Prashant Gupta as Additional and Independent Director of the Company

Dear Sir/Madam,

In accordance with the requirements of Regulation 30 and other applicable Regulations of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), 2015, we hereby inform you that the Board of Directors have appointed Mr. Prashant Gupta (DIN: 08122641) as an Additional and Independent Director, with effect from April 30, 2018 for a tenure of 5 years. Enclosed herewith are the brief details of the appointment as prescribed (Annexure A), the content of which is self explanatory.

Thanking You,

Yours faithfully,
For Eris Lifesciences Limited

Milind Talegaonkar
Company Secretary & Compliance Officer

Encl: a/a

Registered & Corporate Office:

8th Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India

Phone: +91 - 79 - 30451111 / 30179400 - 03 * Fax: +91 - 79 - 30179404 / 30451001 * Email: eris@erislifesciences.com * Web Site: www.eris.co.in

CIN: L24232GJ2007PLC049867

Annexure A

DETAILS IN TERMS OF REGULATION 30 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 READ WITH SEBI CIRCULAR CIR/CFD/CMD/4/2015 SEPTEMBER 09, 2015 ARE AS UNDER:

Sr. No.	Particulars	Details
1	reason for change viz. appointment, resignation, removal, death or otherwise;	Appointment
2	date of appointment/cessation (as applicable) & term of appointment;	April 30, 2018 Appointed as an Additional and Independent Director for a tenure of 5 years
3	brief profile (in case of appointment)	Attached as Annexure B
4	disclosure of relationships between directors (in case of appointment of a director)	NIL

For Eris Lifesciences Limited



Milind Talegaonkar

Company Secretary & Compliance Officer



Shardul Amarchand Mangaldas

CENTURY of EXCELLENCE

PRASHANT GUPTA

Mob + 91 97176 22292

Fax + 91 11 2692 4900

Email prashant.gupta@AMSShardul.com

Annexure-B



Designation | Partner

Practice | Capital Markets

Professional Membership | Bar Council of Delhi,
State Bar of California

Education | B.A. (Juris) & M.A. (Juris),
University of Oxford, England; [B.Com](#) (Hons.);
Shri Ram College of Commerce, University of
Delhi

Mr. Prashant Gupta is a Partner in the firm's corporate department, focusing primarily on capital markets transactions. He represents both issuers and underwriters in various equity and debt capital raising transactions, including initial public offerings, rights issues and QIP offerings, buy-backs, capital restructurings and pre-IPO private placements. Prashant has been recognized by *Who's Who Legal*, *Chambers Asia*, *Indian Lawyer 250*, *Legal500* and other legal industry publications as one of the leading capital markets practitioners in India. He has also been selected by the *Indian Business Law Journal* as one of the top 100 lawyers in India in 2016 and 2017.

Prashant has advised on capital markets transactions that have raised over US\$30 billion globally. Several of the deals, as well as other transactions he has advised on, have been selected as 'Deals of the Year' by the International Financial Law Review (IFLR) Asia, India Business Law Journal, and the Asian-MENA Counsel Magazine. He has also acted on various international capital markets transactions by India focused companies, including the IPOs in the United States (NASDAQ/NYSE) by *MakeMyTrip Limited*, *Azure Power Global Limited*, *Eros International plc*, and *Videocon d2h*, as well as the reorganization and listing on the NYSE by *Vedanta Limited*. He has also advised on the buyback of shares by *Infosys Limited*, which was amongst the largest buybacks in India.

He has advised the underwriters in the US\$3.4 billion IPO by *Coal India Limited* in 2010, which has been the largest IPO in India and acted as sole Indian counsel for the US\$1.7 billion bond offering by *Vedanta Resources*, which has been the largest bond offering by an Indian group.



Shardul Amarchand Mangaldas

CENTURY of EXCELLENCE

Prashant received his Bachelor of Arts in Jurisprudence and Master of Arts in Jurisprudence from the University of Oxford, England, and a Bachelor of Commerce from the Shri Ram College of Commerce, University of Delhi.





Date: February 02, 2018

To The Department of Corporate Services BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001	To National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai-400051
Security Code: 540596	Symbol: ERIS

SUBJECT: CHANGE IN BOARD OF DIRECTORS

Dear Sir/Madam,

In accordance with the requirements of Regulation 30 and other applicable Regulations of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), 2015, we wish to inform that there is a change in the Board of Directors resulting due to resignation of Mr. Shardul Suresh Shroff, Independent Director of the Company, given on account of his personnel commitments. The Cessation is effective from 1st February, 2018.

Kindly take the above intimation on record.

Thanking You,

For Eris Lifesciences Limited

Milind Talegaonkar

Company Secretary & Compliance Officer

Registered & Corporate Office:

8th Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India

Phone: +91 - 79 - 30451111 / 30179400 - 03 • Fax: +91 - 79 - 30179404 / 30451001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in

CIN: L24232GJ2007PLC049867



Date: October 06, 2017

To The Department of Corporate Services BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001 Security Code: 540596	To National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai-400051 Symbol: ERIS
---	--

SUBJECT: CHANGE IN BOARD OF DIRECTORS

Dear Sir/Madam,

In accordance with the requirements of Regulation 30 and other applicable Regulations of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), 2015, we wish to inform that there is a change in the Directors resulting due to resignation of Mr. Rajiv Gulati, Independent Director of the Company. The Cessation is effective from 6th October, 2017.

Kindly take the above intimation on record.

Thanking You,

For Eris Lifesciences Limited

Milind Talegaonkar

Company Secretary & Compliance Officer

Registered & Corporate Office:

8th Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India

Phone: +91 - 79 - 30451111 / 30179400 - 03 • Fax: +91 - 79 - 30179404 / 30451001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in

CIN: L24232GJ2007PLC049867